Objective: Obstructive sleep apnea (OSA) has been associated with metabolic syndrome (MS) and its various components. However, the impact of successful treatment of OSA on MS is still unclear. This study analyzes the prevalence of metabolic syndrome and its various components in patients with OSA and evaluates the impact of uvulopalatopharyngoplasty (UPPP) on MS.
Objective: Obstructive sleep apnea (OSA) has been associated with metabolic syndrome (MS) and its various components. However, the impact of successful treatment of OSA on MS is still unclear. This study analyzes the prevalence of metabolic syndrome and its various components in patients with OSA and evaluates the impact of uvulopalatopharyngoplasty (UPPP) on MS.
Method: A 3-year retrospective chart review of patients referred to an otolaryngology department for sleep disordered breathing. A total of 134 patients met the inclusion criterion. The diagnosis of MS was established according to National Cholesterol Education Program Adult Treatment Panel III.
Results: According to the AHI, the patients were divided into OSA (mean AHI = 64) and controls (mean AHI = 4.46). The incidence of MS was significantly higher in patients with OSA (72.5%) v/s controls (39.5%). The components of MS which showed significance were fasting glucose (P = .002) and blood pressure (P < .032). The prevalence of MS before and 6 months after UPPP was 71.0% and 60.87% which was not statistically significant. The only component of MS showing significant improvement was blood pressure. (P < .001).
Conclusion: There is a high incidence of metabolic syndrome in patients with OSAS. Although UPPP improved respiratory parameters, it did not have a significant effect on the prevalence of MS. The only component which showed a significant improvement was blood pressure.
Sleep Medicine
Thermoplastic Mandibular Advancement Devices for the Treatment of OSAHS Michael Friedman, MD (presenter); Alex Maley; David Taylor; Kanwar Kelley; Kristine Pearson-Chauhan Objective: 1) Report our experience with custom-made and thermoplastic mandibular advancement devices (MADs). 2) Compare the cost, efficacy, and compliance of thermoplastic mandibular advancement devices vs custom made MADs.
Method: Retrospective review of 287 consecutive adult outpatients treated between July 2009 and August 2010. Compliance was assessed using chart review and phone interviews after 1 and 6 months. Endpoints included: 1. Efficacy measured by post-MAD AHI.
Results:
The percentage of patients achieving AHI reduction criteria for efficacy was 70.3% and 72.2% for thermoplastic vs custom-made devices (P = .204). Compliance more than 4 hours a night for 70% of nights within the first month after receiving MAD was 88.2% for thermoplastic vs 64.3% for custom-made (P < .001). At 6 months compliance was 47.4% for thermoplastic devices vs 61.1% for custom devices (P = .01). The average cost for the thermoplastic devices was $150 vs $1450 for the custom-made devices.
Conclusion: Thermoplastic devices resulted in slightly better compliance rate compared with the custom-made devices during the first month after prescription, but reversed at 6 months. Thermoplastic devices have the advantage of significantly lower cost, higher initial acceptance, and comparable efficacy, whereas custom-made devices result in higher long-term compliance.
